The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | STELLAR: genomic sequencing of ctDNA reveals additional driver mutations in Richter’s transformation
Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, outlines ongoing research as part of the ongoing STELLAR trial (NCT03899337) which aims to compare R-CHOP with or without acalabrutinib in patients with newly diagnosed Richter’s transformation (RT). Genomic analysis of tumor tissue and circulating tumor DNA (ctDNA) have revealed a difference in the number of mutations between samples, with additional driver mutations (such as TP53) being identified in ctDNA. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
